Dynamin Inhibitors: MiTMAB™ Series Kit (ab120473)

製品の概要

  • 製品名Dynamin Inhibitors: MiTMAB™ Series Kit
  • 特異性Convenient kit of dynamin inhibitors from the MiTMAB™ chemical series. The inhibitors target dynamin at the lipid binding (PH) domain and inhibit dynamin and endocytosis in enzymatic and cell based assays. They are based on the same chemical scaffold. A negative control compound is also included. Kit contains 1 mg of each of MiTMAB™ (ab120466), OcTMAB™ (ab120467), and Pro-Mystyric Acid (ab120476).
  • 製品の概要

    MiTMABTM chemical series collection

    Convenient kit of dynamin inhibitors from the MiTMAB™ chemical series. The inhibitors target dynamin at the lipid binding (PH) domain and inhibit dynamin and endocytosis in enzymatic and cell based assays. They are based on the same chemical scaffold. A negative control compound is also included. Kit contains 1 mg of each of MiTMAB™ (ab120466), OcTMAB™ (ab120467), and Pro-Mystyric Acid (ab120476).

    Pro-Myristic acid is an in vitro inhibitor of dynamin. Although cell permeable, it is rapidly broken down by cellular esterases to release intracellular myristic acid, which is not a dynamin inhibitor. It can therefore be used as a negative control in cell-based studies. 

    Target

    Description

    PH lipid binding site 

    MiTMAB™: 

    Cell permeable dynamin I and dynamin II inhibitor 

    PH lipid binding site 

    OcTMAB™:

    Cell permeable dynamin I and dynamin II inhibitor 

    PH lipid binding site 

    Pro-Myristic Acid:  

    Negative control for MiTMAB™ and OcTMAB™ 

    Convenient kit of dynamin inhibitors from the MiTMAB™ chemical series. The inhibitors target dynamin at the lipid binding (PH) domain and inhibit dynamin and endocytosis in enzymatic and cell based assays. They are based on the same chemical scaffold. A negative control compound is also included. Kit contains 1 mg of each of MiTMAB™ ab120476.

  • 特記事項

    Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 6 months.

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. MiTMAB™ and OcTMAB™ are trademarks of Children's Medical Research Institute and Newcastle Innovation Ltd.

    Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. MiTMAB™ is a trademark of Children's Medical Research Institute and Newcastle Innovation Ltd
  • アプリケーション適用あり: Functional Studiesmore details

製品の特性

    アプリケーション

    Our Abpromise guarantee covers the use of ab120473 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    アプリケーション Abreviews 特記事項
    Functional Studies Use at an assay dependent concentration.

    Dynamin Inhibitors: MiTMAB™ Series Kit 画像

    • ab66705 staining PAI1 in HeLa cells treated with OcTMAB™ (ab120467), by ICC/IF. Increase in PAI1 expression correlates with increased concentration of OcTMAB™, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120467 (OcTMAB™) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab66705 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
    • ab66705 staining PAI1 in HeLa cells treated with MiTMAB™ (ab120466), by ICC/IF. Increase in PAI1 expression correlates with increased concentration of MiTMAB™, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120466 (MiTMAB™) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab66705 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    Dynamin Inhibitors: MiTMAB™ Series Kit (ab120473) 使用論文

    ab120473 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab120473.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"